Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice

Anti-vascular endothelial growth factor (VEGF) agents are the mainstay treatment for various angiogenesis-related retinal diseases. Currently, bevacizumab, a recombinant humanized anti-VEGF antibody, is trailed in retinopathy of prematurity, a vasoproliferative retinal disorder in premature infants....

Descripción completa

Detalles Bibliográficos
Autores principales: Jo, Dong Hyun, Park, Sung Wook, Cho, Chang Sik, Powner, Michael B., Kim, Jin Hyoung, Fruttiger, Marcus, Kim, Jeong Hun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520452/
https://www.ncbi.nlm.nih.gov/pubmed/26226015
http://dx.doi.org/10.1371/journal.pone.0134308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520452/
https://www.ncbi.nlm.nih.gov/pubmed/26226015
http://dx.doi.org/10.1371/journal.pone.0134308

Ejemplares similares